MoonLake Immunotherapeutics
MLTX
$13.35
$0.836.63%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -97.02% | -127.56% | -192.14% | -513.20% | -275.46% |
| Total Depreciation and Amortization | 112.25% | 116.96% | 15.24% | 261.07% | 10,536.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 103.11% | -16.01% | 44.52% | -123.41% | 285.36% |
| Change in Net Operating Assets | 158.72% | 77.65% | 87.03% | 39.24% | 752.86% |
| Cash from Operations | -76.23% | -95.52% | -155.15% | -292.68% | -173.24% |
| Capital Expenditure | 100.00% | -- | 83.49% | 38.30% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 51.34% | 200.58% | 296.84% | -225.61% | 133.50% |
| Cash from Investing | 51.68% | 200.58% | 295.27% | -226.07% | 133.42% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 427.47% | -- | -99.81% | -99.52% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Financing | 162.30% | -- | 43.44% | -99.47% | -- |
| Foreign Exchange rate Adjustments | 12.31% | 8,282.35% | -291.30% | 555.02% | -6,600.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 34.05% | 130.36% | 1,153.30% | -246.79% | 117.90% |